(Q28082019)

Carol A. Kauffman

series ordinal

2

1 reference

language of work or name

1 reference

15 November 2015

1 reference

Clinical Infectious Diseases

published in

1 reference

volume

61

1 reference

issue

10

1 reference

page(s)

1558-65

1 reference

Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV571

Isavuconazole: a comprehensive review of spectrum of activity of a new triazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV571

In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV571

Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV571

Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV571

In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV571

Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV571

In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV571

In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV571

In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV571

In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV571

Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV571

In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV571

In vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV571

Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV571

Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV571

In vitro activities of eight antifungal drugs against 106 waterborne and cutaneous exophiala species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV571

In vitro susceptibility patterns of clinically important Trichophyton and Epidermophyton species against nine antifungal drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV571

Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in h

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV571

Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV571

Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV571

Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV571

Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV571

A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV571

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV571

Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV571

Epidemiology and outcome of zygomycosis: a review of 929 reported cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV571

A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV571

Posaconazole as salvage therapy for zygomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV571

Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV571